Does the media refer more to AMLX or HALO?

In the previous week, Halozyme Therapeutics had 3 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 7 mentions for Halozyme Therapeutics and 4 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Halozyme Therapeutics' score of 0.19 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BBIO or AMLX?

In the previous week, BridgeBio Pharma and BridgeBio Pharma both had 4 articles in the media. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat BridgeBio Pharma's score of 0.51 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SMMT or AMLX more profitable?

Amylyx Pharmaceuticals' return on equity of -52.92% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media refer more to SMMT or AMLX?

In the previous week, Summit Therapeutics had 16 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 20 mentions for Summit Therapeutics and 4 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Summit Therapeutics' score of 0.42 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMLX or MDGL?

In the previous week, Amylyx Pharmaceuticals had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 4 mentions for Amylyx Pharmaceuticals and 2 mentions for Madrigal Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Madrigal Pharmaceuticals' score of 0.57 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMLX or BMRN?

In the previous week, BioMarin Pharmaceutical had 5 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 9 mentions for BioMarin Pharmaceutical and 4 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat BioMarin Pharmaceutical's score of 0.68 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Amylyx Pharmaceuticals (AMLX) Competitors

$27.79 -0.29 (-1.03%)

Closing price 04:00 PM Eastern

Extended Trading

$27.80 +0.02 (+0.05%)

As of 07:30 PM Eastern

Compare

AMLX vs. HALO, BBIO, SMMT, MDGL, and BMRN

Should you buy Amylyx Pharmaceuticals stock or one of its competitors? Amylyx Pharmaceuticals's main competitors and comparable companies include Halozyme Therapeutics (HALO), BridgeBio Pharma (BBIO), Summit Therapeutics (SMMT), Madrigal Pharmaceuticals (MDGL), and BioMarin Pharmaceutical (BMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Amylyx Pharmaceuticals compare to Halozyme Therapeutics?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Amylyx Pharmaceuticals has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

In the previous week, Halozyme Therapeutics had 3 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 7 mentions for Halozyme Therapeutics and 4 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Halozyme Therapeutics' score of 0.19 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Amylyx Pharmaceuticals presently has a consensus target price of $38.86, indicating a potential upside of 38.42%. Halozyme Therapeutics has a consensus target price of $91.20, indicating a potential downside of 16.41%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Halozyme Therapeutics has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	35.80	-$144.74M	-$1.43	N/A
Halozyme Therapeutics	$1.40B	8.87	$316.89M	$3.35	32.57

Halozyme Therapeutics has a net margin of 24.86% compared to Amylyx Pharmaceuticals' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Summary

Halozyme Therapeutics beats Amylyx Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market.

In the previous week, BridgeBio Pharma and BridgeBio Pharma both had 4 articles in the media. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat BridgeBio Pharma's score of 0.51 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.13	-$724.93M	-$3.57	N/A
Amylyx Pharmaceuticals	$87.37M	35.80	-$144.74M	-$1.43	N/A

BridgeBio Pharma presently has a consensus price target of $102.61, indicating a potential upside of 52.87%. Amylyx Pharmaceuticals has a consensus price target of $38.86, indicating a potential upside of 38.42%. Given BridgeBio Pharma's higher probable upside, equities research analysts plainly believe BridgeBio Pharma is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

BridgeBio Pharma and Amylyx Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Summit Therapeutics currently has a consensus target price of $28.61, indicating a potential upside of 70.04%. Amylyx Pharmaceuticals has a consensus target price of $38.86, indicating a potential upside of 38.42%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Amylyx Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Amylyx Pharmaceuticals	$87.37M	35.80	-$144.74M	-$1.43	N/A

Summit Therapeutics has a beta of -1.51, meaning that its stock price is 251% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.1, meaning that its stock price is 110% less volatile than the broader market.

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Amylyx Pharmaceuticals' return on equity of -52.92% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

In the previous week, Summit Therapeutics had 16 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 20 mentions for Summit Therapeutics and 4 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Summit Therapeutics' score of 0.42 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amylyx Pharmaceuticals beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Madrigal Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Amylyx Pharmaceuticals has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	35.80	-$144.74M	-$1.43	N/A
Madrigal Pharmaceuticals	$958.40M	11.94	-$288.28M	-$12.89	N/A

Amylyx Pharmaceuticals has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, indicating that its stock price is 204% less volatile than the broader market.

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Amylyx Pharmaceuticals had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 4 mentions for Amylyx Pharmaceuticals and 2 mentions for Madrigal Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Madrigal Pharmaceuticals' score of 0.57 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Amylyx Pharmaceuticals' return on equity of -52.92% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Amylyx Pharmaceuticals presently has a consensus price target of $38.86, suggesting a potential upside of 38.42%. Madrigal Pharmaceuticals has a consensus price target of $710.20, suggesting a potential upside of 43.39%. Given Madrigal Pharmaceuticals' higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Amylyx Pharmaceuticals beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to BioMarin Pharmaceutical?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

BioMarin Pharmaceutical has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	35.80	-$144.74M	-$1.43	N/A
BioMarin Pharmaceutical	$3.22B	3.46	$348.90M	$0.37	155.50

Amylyx Pharmaceuticals has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BioMarin Pharmaceutical had 5 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 9 mentions for BioMarin Pharmaceutical and 4 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat BioMarin Pharmaceutical's score of 0.68 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has a net margin of 2.14% compared to Amylyx Pharmaceuticals' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Amylyx Pharmaceuticals presently has a consensus target price of $38.86, suggesting a potential upside of 38.42%. BioMarin Pharmaceutical has a consensus target price of $89.17, suggesting a potential upside of 54.99%. Given BioMarin Pharmaceutical's higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

BioMarin Pharmaceutical beats Amylyx Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get Amylyx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMLX vs. The Competition

Export

Metric	Amylyx Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.13B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.77%
P/E Ratio	-19.43	12.93	273.67	26.04
Price / Sales	35.44	1,308.36	612.51	90.64
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	10.00	16.63	10.92	6.30
Net Income	-$144.74M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-5.76%	-3.05%	-2.11%	-1.67%
1 Month Performance	-19.43%	-10.75%	-6.34%	-3.94%
1 Year Performance	109.10%	21.11%	8.81%	2.77%

Amylyx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMLX Amylyx Pharmaceuticals	3.5892 of 5 stars	$27.79 -1.0%	$38.86 +39.8%	+100.6%	$3.13B	$87.37M	N/A	136	News Coverage
HALO Halozyme Therapeutics	2.7512 of 5 stars	$112.89 -0.9%	$91.20 -19.2%	+42.7%	$12.93B	$1.40B	33.70	423	Insider Trade
BBIO BridgeBio Pharma	3.0956 of 5 stars	$66.61 +1.6%	$102.61 +54.0%	+25.1%	$12.82B	$502.08M	N/A	839
SMMT Summit Therapeutics	2.8723 of 5 stars	$15.48 -0.8%	$25.91 +67.4%	-18.5%	$12.45B	N/A	N/A	265	Analyst Forecast
MDGL Madrigal Pharmaceuticals	3.0007 of 5 stars	$517.04 +0.1%	$710.20 +37.4%	+11.3%	$11.93B	$958.40M	N/A	915

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMLX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. HALO, BBIO, SMMT, MDGL, and BMRN

How does Amylyx Pharmaceuticals compare to Halozyme Therapeutics?

Summary

How does Amylyx Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Amylyx Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Amylyx Pharmaceuticals compare to Madrigal Pharmaceuticals?

Summary

How does Amylyx Pharmaceuticals compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. HALO, BBIO, SMMT, MDGL, and BMRN

How does Amylyx Pharmaceuticals compare to Halozyme Therapeutics?

Which has more risk & volatility, AMLX or HALO?

Does the media refer more to AMLX or HALO?

Do institutionals and insiders have more ownership in AMLX or HALO?

Do analysts rate AMLX or HALO?

Which has higher valuation and earnings, AMLX or HALO?

Is AMLX or HALO more profitable?

Summary

How does Amylyx Pharmaceuticals compare to BridgeBio Pharma?

Do institutionals and insiders believe in BBIO or AMLX?

Is BBIO or AMLX more profitable?

Which has more risk and volatility, BBIO or AMLX?

Does the media prefer BBIO or AMLX?

Which has preferable earnings and valuation, BBIO or AMLX?

Do analysts prefer BBIO or AMLX?

Summary

How does Amylyx Pharmaceuticals compare to Summit Therapeutics?

Do analysts rate SMMT or AMLX?

Which has stronger valuation and earnings, SMMT or AMLX?

Which has more volatility & risk, SMMT or AMLX?

Do institutionals and insiders have more ownership in SMMT or AMLX?

Is SMMT or AMLX more profitable?

Does the media refer more to SMMT or AMLX?

Summary

How does Amylyx Pharmaceuticals compare to Madrigal Pharmaceuticals?

Which has stronger valuation and earnings, AMLX or MDGL?

Which has more volatility and risk, AMLX or MDGL?

Do insiders & institutionals have more ownership in AMLX or MDGL?

Does the media prefer AMLX or MDGL?

Is AMLX or MDGL more profitable?

Do analysts recommend AMLX or MDGL?

Summary

How does Amylyx Pharmaceuticals compare to BioMarin Pharmaceutical?

Which has stronger valuation & earnings, AMLX or BMRN?

Which has more risk and volatility, AMLX or BMRN?

Do insiders & institutionals hold more shares of AMLX or BMRN?

Does the media prefer AMLX or BMRN?

Is AMLX or BMRN more profitable?

Do analysts prefer AMLX or BMRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools